[Interferon therapy in multiple myeloma].
Multiple myeloma is a B-cell malignancy characterised by a clonal expansion of plasma cells. Prognosis of the disease can be based upon clinical stage and biological features of myeloma cells as well as of their products. Cytostatic therapy is a standard in the treatment of multiple myeloma. A new aspect is the therapeutic administration of recombinant interferons (rIFNs). Some experience has been gathered that chemotherapy-induced remissions (plateau phase) can be maintained by IFN-therapy. In induction therapy, IFN in combination with cytostatic agents has some therapeutical relevance, either. The administration of IFN in the treatment of multiple myeloma represents a new therapeutic strategy.